Sector Alpha Week of 2026-08-05
Sector Alpha — machine-written from the numbers · Data as of 2026-08-05

The Charles Schwab Corporation

SCHW
Financials · Capital Markets

The Charles Schwab Corporation's earnings have outrun its stock. EPS grew +55.5% in a year against a +11.3% price move.

The sharpest disagreement: annual EPS moved +55.5% against a +11.3% price move — the market has not yet caught up with the delivery.

The price is in a confirmed uptrend (6 weeks in) while the P/BV sits at the 90th percentile of its own 5-year range. Underneath, the last four quarters read improving — profit +31.5% year on year, with the the net margin at 39.6%. What settles it: whether the price catches up with earnings that have already moved.

Stage
Improving
fundamental trajectory, 12 quarters
Price
$106
+11.3% 1Y
P/BV
3.7×
90th pctile
of its own 5-year range
Revenue (Jun 26)
$7.1 B
+20.9% YoY
Profit (Jun 26)
$2.8 B
+31.5% YoY
Net margin
39.6%
+3.2 pp YoY
ROE
20%
FY25
ROA
2.07%
latest
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

The Charles Schwab Corporation trades at $106, in a confirmed uptrend and 6 weeks into that stage. That is +11.2% against its own 200-day average. It sits at 100% of a 52-week range of $87 to $106. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 4 straight weeks.

Today the stock is in a confirmed uptrend — week 6 of stage 2. At $106 it trades +11.2% versus its 200-day average and sits at 100% of its 52-week range ($87–$106).

Aug 26: $106 Weekly closing price ($) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
+11.2% versus the 200-day line, week 6 of stage 2
Price50-day avg200-day avg
S4S3S2S1S2S2S1$111$94.5$78.2$61.9$45.6$$106$96Jul 23Apr 24Jan 25Oct 25Aug 26
S4S3S2S1S2S2S1$111$94.5$78.2$61.9$45.6$$106$96Jul 23Jan 25Aug 26
Beating or trailing, week by week since 2016 Each cell is one week from 2016 to now (527 weeks): the stock's trailing 13-week return minus the S&P 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the S&P 500 reading is not held.
trailing 13-week return vs the S&P 500
Jul 16Aug 26

Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +313% while the S&P 500 moved +263% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 4 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation For a bank we price the book, not the earnings: P/BV is what the market pays for each $1 of the bank's net worth. A bank below 1× book is priced below the value of what it owns, net of what it owes.

The Charles Schwab Corporation trades at 3.7× P/BV, at the pricey end of its own range (90th percentile). Its long-run median P/BV is 3.0×, measured across 5.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/BV of 3.7× is at the pricey end of its own range (90th percentile), against a long-run median of 3.0× measured over 5.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

P/BV 3.7× vs a 3.0× long-run median P/BV, weekly (left axis); book value per share, quarterly steps drawn weekly (right axis). 5.1-year window; brief peaks above 4.2× shown pinned at the top. The book value / share bars are red where the reading is lower than the quarter before.
at the pricey end of its own range (90th percentile)
P/BVMedianBook value / share (quarterly)
4.4×$32.73.8×$24.53.2×$16.42.7×$8.22.1×$0.0×$3.78×$28Jul 21Oct 22Jan 24Apr 25Aug 26
4.4×$32.73.8×$24.53.2×$16.42.7×$8.22.1×$0.0×$3.78×$28Jul 21Jan 24Aug 26
PEG 0.80 PEG ratio per quarter — the P/E divided by the earnings-growth rate. The dashed line marks 1.0: below it the growth is cheap against the multiple, above it the price already prices the growth in. Last 20 quarters.
below 1.0, the growth looks cheap against the multiple
PEGPEG = 1.0
2.6×2.1×1.6×1.0×0.5××0.80×Sep 21Sep 22Dec 23Mar 25Jun 26
2.6×2.1×1.6×1.0×0.5××0.80×Sep 21Dec 23Jun 26
P/BV
3.7×
90th percentile of 5y
PEG
0.72
as reported

Why the multiple sits where it does: over the past year book value grew while the price moved +11.3% — the price ran ahead of the book, pushing the multiple up its own range.

The price move, decomposed: over 5y, of the +8.1%/yr price move, ~−1.5%/yr came from book-value growth and ~+9.6 pp from the multiple (expanding). The split is the honest approximate (price return minus book-value growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is full against its own past, so the story rests on the book-value line underneath it, not the multiple.

03 · Stage: Improving

Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

The Charles Schwab Corporation reads as improving on its fundamental arc. Improving — EPS growth bottomed 8 quarters ago at −29.7% and has held its recovery at +47.8%, ROE lifting at 19.2%. The read is built from 12 quarters across 4 curves, on full evidence.

Growth, year by year: revenue +22.0% in FY25, profit +49.0% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoYProfit YoYEPS YoY
24%62%15%38%6.4%13%−2.6%−12%−12%−36%%%22%49%FY21FY23FY25
24%62%15%38%6.4%13%−2.6%−12%−12%−36%%%22%49%FY21FY23FY25
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue stabilising, profit rolling over
RevenueProfitEPS
25%75%15%45%4.7%16%−5.5%−13%−16%−43%%%20.3%38.5%47.8%Sep 23Dec 24Jun 26
25%75%15%45%4.7%16%−5.5%−13%−16%−43%%%20.3%38.5%47.8%Sep 23Dec 24Jun 26
ROE Trailing-twelve-month net profit as a share of quarter-end equity, %.
the return curve, computed quarterly
ROE
20%17%15%13%10%%19.2%Sep 23Mar 24Dec 24Sep 25Jun 26
20%17%15%13%10%%19.2%Sep 23Dec 24Jun 26
Revenue growth
Flat
latest +20.3% · span −12.9% to +22.3%
Profit growth
Rolling over
latest +38.5% · span −34.7% to +60.3%
EPS growth
Flat
latest +47.8% · span −34.7% to +66.8%
ROE
Rising
latest 19.2% · span 10.9%–19.2%

Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; stock price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+22.0%+4.8%
Profit+49.0%+7.2%
EPS+55.5%+9.9%
Stock price+11.3%+17.9%+8.1%+13.5%
Revenue YoY (Jun 26)
+20.9%
latest quarter vs a year ago
Profit YoY (Jun 26)
+31.5%
latest quarter vs a year ago
Revenue 10y
6.6%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

60.9/100 — rank 5 of 27 in Capital Markets · 80% evidence confidence

The Charles Schwab Corporation scores 60.9 out of 100 against the 27 companies it is compared with in Capital Markets, ranking 5. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 22.8 + 15.6 + 8.7 + 13.8 = 60.9. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if ROA rolls over or gross NPA rises while sector-relative strength deteriorates.

05 · Revenue

Revenue For a bank, revenue is everything the franchise earns — interest on the loan book plus fees from its businesses.

The Charles Schwab Corporation reported $7.1 B of income in the Jun 26 quarter, +20.9% year on year. That is the 9th straight quarter of year-on-year growth. Over 4 years it has compounded at 6.6% a year. The last full year, FY25, came in at $23.9 B. The last four reported quarters add to $26.0 B.

FY25 revenue came in at $23.9 B (+22.0% on the year), capping 4 years at 6.6% compound. The latest quarter (Jun 26) printed $7.1 B, +20.9% year on year — the 9th consecutive quarter of year-over-year growth.

FY25 revenue $23.9 B (+22.0% YoY) Revenue bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
6.6% a year over 4 years
RevenueYoY growth
2624%1915%136.4%6.5−2.6%0.0−12%$ B%$24B22%FY21FY23FY25
2624%1915%136.4%6.5−2.6%0.0−12%$ B%$24B22%FY21FY23FY25
Jun 26: $7.1 B (+20.9% YoY) Quarterly revenue bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
9th straight quarter of growth
Revenue (quarterly)YoY growth
7.630%5.717%3.83.8%1.9−9.4%0.0−23%$ B%$7B20.9%Sep 23Dec 24Jun 26
7.630%5.717%3.83.8%1.9−9.4%0.0−23%$ B%$7B20.9%Sep 23Dec 24Jun 26

Pace check: the last four quarters averaged +20.5% growth against the decade's 6.6% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +20.3% over the last 4 quarters against +18.6%/yr over the last 8 — stabilising; TTM profit +38.5% vs +44.2%/yr — rolling over.

06 · Net margin

Net margin Net margin — what the bank keeps of every $100 of revenue after every cost, provision and tax. With big fee businesses in the mix, it is the cleanest margin we can read for this bank.

The Charles Schwab Corporation's net margin is 39.6% in the Jun 26 quarter, +3.2 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the net margin has ranged 26.9% to 37.0%. The current quarter is running above every full year in that window.

The latest quarter's net margin is 39.6%, +3.2 pp against the same quarter a year ago. Across 5 fiscal years the net margin has ranged 26.9%–37.0%, and FY25's 37.0% is the top of that band — a record year.

Why: the numbers show the net margin move clearly, but the cost lines behind it sit below what we hold — so we state the move without inventing its driver.

Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.

FY25: 37.0% Net margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 5-year window.
the widest a 26.9–37.0% band over 5 years
net marginYoY change (pp)
38%7.9%35%3.7%32%−0.5%29%−4.7%26%−8.9%%%37%6.7%FY21FY23FY25
38%7.9%35%3.7%32%−0.5%29%−4.7%26%−8.9%%%37%6.7%FY21FY23FY25
Jun 26: 39.6% net margin (+3.2 pp YoY) Quarterly net margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Net profit as a share of total revenue, per quarter.
Net marginYoY change (pp)
41%13%36%6.2%31%−0.7%27%−7.5%22%−14%%%39.6%3.2%Sep 23Dec 24Jun 26
41%13%36%6.2%31%−0.7%27%−7.5%22%−14%%%39.6%3.2%Sep 23Dec 24Jun 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

The Charles Schwab Corporation earned $2.8 B of net profit in the Jun 26 quarter, +31.5% year on year. It is the 9th consecutive quarter of growth. Full-year FY25 profit was $8.8 B. The 4-year compound rate is 10.9%. That is 39.6% of the quarter's revenue. The same quarter a year earlier earned $2.1 B.

Jun 26 profit was $2.8 B, +31.5% year on year — the 9th consecutive quarter of growth. On the full year, FY25 printed $8.8 B (+49.0%), and the 4-year compound rate is 10.9%.

FY25 profit $8.8 B (+49.0% YoY) Net profit bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
10.9% a year over 4 years
Net profitYoY growth
9.655%7.233%4.89.8%2.4−13%0.0−36%$ B%$9B49%FY21FY23FY25
9.655%7.233%4.89.8%2.4−13%0.0−36%$ B%$9B49%FY21FY23FY25
Jun 26: $2.8 B (+31.5% YoY) Quarterly net profit bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
9th straight quarter of growth
Net profit (quarterly)YoY growth
3.087%2.351%1.515%0.8−21%0.0−57%$ B%$3B31.5%Sep 23Dec 24Jun 26
3.087%2.351%1.515%0.8−21%0.0−57%$ B%$3B31.5%Sep 23Dec 24Jun 26

Why profit moved: revenue contributed +20.9% and the margin +3.2 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.

Pace comparison, last four quarters: profit +40.6% vs revenue +20.5%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.

08 · Asset quality — the ladder

Asset quality — the ladder Gross NPA is the slice of the loan book where repayments have stopped. Net NPA is what remains after the money already set aside against those loans. Falling is healing; rising is damage arriving.

Loan-book quality history is not available for The Charles Schwab Corporation, so this section names the gap rather than estimating a ratio. No gross or net non-performing-asset series is filed in a form this page can read, and none is inferred from the profit line. The income, margin and return sections above carry the evidence this business does report.

We do not hold quarterly loan-book quality numbers for this bank, so this section states that plainly rather than working around it.

Why: loan-book quality is the engine room of a bank, and its drivers — slippages, recoveries, provisioning — sit below what we hold for this name; the sections around it carry the reads we can stand behind.

09 · The loan book

The loan book We read the loan book through revenue — when the book and the businesses grow, revenue grows with them. It is a rough proxy, and we say so: rate moves and fee swings can shift it a few points in any one year.

The Charles Schwab Corporation's revenue grew +22.0% in FY25 to $23.9 B, so the book is growing. The latest quarter ran +20.9% year on year. The net margin on that income is 39.6%, +3.2 percentage points against a year ago. Interest income is a proxy for the book; rate moves can shift it a few points in any one year.

FY25 revenue was $23.9 B, +22.0% on the year, and the latest quarter ran +20.9% year on year. The net margin on that revenue is 39.6% this quarter (+3.2 pp YoY) — growth with a widening margin on it.

FY25: revenue $23.9 B (+22.0% YoY) with the net margin at 37.0% Revenue by fiscal year, $ B (bars, left); net margin, % (line, right). 5-year window. A bar is red when it is lower than the year before.
RevenueNet margin
2638%1935%1332%6.529%0.026%$ B%$24B37%FY21FY22FY23FY24FY25
2638%1935%1332%6.529%0.026%$ B%$24B37%FY21FY23FY25

The synthesis: a lender compounds when the book grows while the margin holds and the loan book stays clean — with quarterly loan-quality numbers missing here, revenue growth and margin are the two we watch.

10 · Returns on equity and assets

Returns on equity and assets Two numbers rate a bank: ROE — what it earns on shareholder money — and ROA — what it earns on everything it deploys. ROE above ~13–15% earns its keep; below that, growth builds book slowly.

The Charles Schwab Corporation earns a return on equity of 18% in FY25. Its trough over the ladder below was 10% in FY21. On the asset side every $100 of the balance sheet earned about $2.07, which is the return before leverage is applied.

FY25 ROE came in at 18%, recovered from a FY21 trough of 10%. On assets, the latest reading is about 2.07% — every $100 the bank deploys earns roughly $2.07 a year. That clears the bar a bank must beat for its book value to compound.

FY25: ROE 18%, ROA 1.80% Return on equity by fiscal year, % (line, left); return on assets, % (line, right). 5-year window. A lender is judged on ROE and ROA — return on invested capital does not apply to a bank.
up from a FY21 trough of 10%
ROEROA
20%1.9%18%1.6%15%1.4%12%1.2%9.7%0.9%%%17.9%1.8%FY21FY23FY25
20%1.9%18%1.6%15%1.4%12%1.2%9.7%0.9%%%17.9%1.8%FY21FY23FY25
Jun 26: ROE 11.3% (TTM), ROA 2.70% Trailing-twelve-month return on equity (left) and on assets (right), per quarter, %. Last 12 quarters, anchored to the annual figure.
ROE (TTM)ROA (TTM)
12%2.8%9.5%2.3%7.0%1.8%4.5%1.3%2.0%0.8%%%11.3%2.7%Sep 23Dec 24Jun 26
12%2.8%9.5%2.3%7.0%1.8%4.5%1.3%2.0%0.8%%%11.3%2.7%Sep 23Dec 24Jun 26

Why ROE moved: profit compounded 10.9% a year over 4 years while the equity base grew more slowly — earnings recovering faster than book value builds is what lifts ROE off a trough.

11 · Dividend

Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.

The Charles Schwab Corporation paid $1.13 per share over the last four reported quarters, up 18.5% on a year ago. The most recent declaration was $0.32 for Mar 26. Against the current price of $106 that is a trailing yield of 1.06%, measured on dividends already paid rather than on a forecast.

The Charles Schwab Corporation paid $1.13 per share across the last four reported quarters, most recently $0.32 for Mar 26. That is up 18.5% against the same quarter a year earlier. Against the current price of $106 the trailing twelve months work out to 1.06% — trailing dividends measured against today's price, not a forward estimate.

Dividend per share by quarter Declared dividend per share, $ B, per reported quarter. 11 quarters on file.
latest $0.32 (Mar 26)
Dividend per share
0.350.260.170.090.00$ B$0BSep 23Mar 24Dec 24Jun 25Mar 26
0.350.260.170.090.00$ B$0BSep 23Dec 24Mar 26
12 · Debt

Debt

For a bank, borrowings are raw material, not a warning sign — solvency is read through the returns and the loan book. A manufacturer’s debt is a claim against its profits, so the debt-to-equity lens that works everywhere else misleads on a lender and is not applied here.

A manufacturer’s debt is a claim against its profits; a bank’s borrowings are its inventory — money taken in to be lent out. The debt lens that works everywhere else misleads here, so this page does not apply it. The solvency questions for a bank — is the loan book sound, is the equity earning — are read through the loan-book and returns sections above.

13 · Ownership

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

0.0% of The Charles Schwab Corporation's tradable float is currently sold short — the crowd is not positioned against this stock. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead. It is a single point-in-time reading, and its history is not held.

The latest reading: 0.0% of the float is sold short. The crowd is not positioned against this stock. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.

Short interest
0.0%
of the tradable float

Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.

14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

The Charles Schwab Corporation: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre. The Z-score was built for manufacturers and is not applied to banks and lenders, so solvency here is read from the capital and asset-quality lines instead.

The safety line in one sentence: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre.

15 · Related companies · Capital Markets
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1Marex Group LimitedMRX 65.0/100Favorable setup76% evidence LEADER 24.0/35 Income 32.6% · PAT 40.9% 71% evidence 12.4/25 ROA 0.6% · ROE 9.4% · GNPA — 68% evidence 9.5/20 P/BV 2.56× · P/BV÷ROE 0.27 70% evidence 19.1/20 RS sector 33.4% · RS bench 31.9% · 1Y 81.1%12 of 12 weeks ahead 100% evidence
Exact sum: 24 + 12.4 + 9.5 + 19.1 = 65 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
2Morgan StanleyMS 63.1/100Mixed-positive evidence80% evidence LEADER 21.1/35 Income 18% · PAT 36.8% 81% evidence 13.7/25 ROA 0.8% · ROE 10.3% · GNPA — 68% evidence 11.3/20 P/BV 2.27× · P/BV÷ROE 0.22 70% evidence 17.0/20 RS sector 10.2% · RS bench 9% · 1Y 51.6%12 of 12 weeks ahead 100% evidence
Exact sum: 21.1 + 13.7 + 11.3 + 17 = 63.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
3Virtu Financial, Inc.VIRT 63.0/100Mixed-positive evidence60% evidence LEADER 14.1/35 Income — · PAT — 26% evidence 16.8/25 ROA 1.3% · ROE 14.4% · GNPA — 68% evidence 13.9/20 P/BV 2.21× · P/BV÷ROE 0.15 70% evidence 18.2/20 RS sector 19.7% · RS bench 18.4% · 1Y 34.3%12 of 12 weeks ahead 100% evidence
Exact sum: 14.1 + 16.8 + 13.9 + 18.2 = 63 · Decision use: Price leads the evidence: RS versus the benchmark is 18.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
4StoneX Group Inc.SNEX 62.2/100Mixed-positive evidence62% evidence FADING 24.5/35 Income 38% · PAT 56.1% 55% evidence 13.0/25 ROA — · ROE 7.6% · GNPA — 34% evidence 8.0/20 P/BV 2.36× · P/BV÷ROE 0.31 70% evidence 16.7/20 RS sector 22.5% · RS bench 21% · 1Y 89.6%9 of 12 weeks ahead 100% evidence
Exact sum: 24.5 + 13 + 8 + 16.7 = 62.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5The Charles Schwab Corporationthis pageSCHW 60.9/100Mixed-positive evidence80% evidence TURNING 22.8/35 Income 20.3% · PAT 38.6% 81% evidence 15.6/25 ROA 1.2% · ROE 11.3% · GNPA — 68% evidence 8.7/20 P/BV 3.32× · P/BV÷ROE 0.29 70% evidence 13.8/20 RS sector 0.8% · RS bench -0.1% · 1Y 9.5%4 of 12 weeks ahead 100% evidence
Exact sum: 22.8 + 15.6 + 8.7 + 13.8 = 60.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6Piper Sandler CompaniesPIPR 52.6/100Mixed-positive evidence60% evidence BASING 21.7/35 Income — · PAT — 26% evidence 18.1/25 ROA 7.2% · ROE 10% · GNPA — 68% evidence 7.0/20 P/BV 3.87× · P/BV÷ROE 0.39 70% evidence 5.8/20 RS sector -15.8% · RS bench -16.7% · 1Y -5.7%0 of 12 weeks ahead 100% evidence
Exact sum: 21.7 + 18.1 + 7 + 5.8 = 52.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
7Evercore Inc.EVR 51.5/100Mixed-positive evidence60% evidence BASING 20.9/35 Income — · PAT — 26% evidence 18.9/25 ROA 6.1% · ROE 11.1% · GNPA — 68% evidence 5.8/20 P/BV 6.48× · P/BV÷ROE 0.58 70% evidence 5.9/20 RS sector -12% · RS bench -12.9% · 1Y 8.1%4 of 12 weeks ahead 100% evidence
Exact sum: 20.9 + 18.9 + 5.8 + 5.9 = 51.5 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
8PJT Partners Inc.PJT 50.4/100Mixed-positive evidence60% evidence TURNING 20.0/35 Income — · PAT — 26% evidence 17.4/25 ROA 5% · ROE 8.9% · GNPA — 68% evidence 3.5/20 P/BV 12.38× · P/BV÷ROE 1.39 70% evidence 9.5/20 RS sector -5.6% · RS bench -6.6% · 1Y -3%4 of 12 weeks ahead 100% evidence
Exact sum: 20 + 17.4 + 3.5 + 9.5 = 50.4 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
9LPL Financial Holdings Inc.LPLA 49.4/100Mixed-negative evidence60% evidence TURNING 16.4/35 Income — · PAT — 26% evidence 15.3/25 ROA 2.4% · ROE 7% · GNPA — 68% evidence 6.4/20 P/BV 3.91× · P/BV÷ROE 0.56 70% evidence 11.3/20 RS sector -3.6% · RS bench -4.4% · 1Y -4.2%2 of 12 weeks ahead 100% evidence
Exact sum: 16.4 + 15.3 + 6.4 + 11.3 = 49.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
10The Goldman Sachs Group, Inc.GS 48.8/100Mixed-negative evidence80% evidence BREAKING OUT 16.8/35 Income 17.8% · PAT 34.8% 81% evidence 9.2/25 ROA 0.3% · ROE 5.4% · GNPA — 68% evidence 7.2/20 P/BV 2.03× · P/BV÷ROE 0.38 70% evidence 15.6/20 RS sector 7.6% · RS bench 6.4% · 1Y 46%10 of 12 weeks ahead 100% evidence
Exact sum: 16.8 + 9.2 + 7.2 + 15.6 = 48.8 · Decision use: Price leads the evidence: RS versus the benchmark is 6.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
11Interactive Brokers Group, Inc.IBKR 48.0/100Mixed-negative evidence60% evidence FADING 16.8/35 Income — · PAT — 26% evidence 10.8/25 ROA 0.6% · ROE 6.6% · GNPA — 68% evidence 5.0/20 P/BV 6.57× · P/BV÷ROE 0.99 70% evidence 15.4/20 RS sector 9.2% · RS bench 8% · 1Y 34.5%10 of 12 weeks ahead 100% evidence
Exact sum: 16.8 + 10.8 + 5 + 15.4 = 48 · Decision use: Price leads the evidence: RS versus the benchmark is 8%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
12Stifel Financial Corp.SF 46.7/100Mixed-negative evidence60% evidence TURNING 16.2/35 Income — · PAT — 26% evidence 8.4/25 ROA -2% · ROE 8.1% · GNPA — 68% evidence 11.0/20 P/BV 1.9× · P/BV÷ROE 0.23 70% evidence 11.1/20 RS sector -2.2% · RS bench -3.1% · 1Y 12.9%1 of 12 weeks ahead 100% evidence
Exact sum: 16.2 + 8.4 + 11 + 11.1 = 46.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
13Moelis & CompanyMC 46.6/100Mixed-negative evidence60% evidence TURNING 17.5/35 Income — · PAT — 26% evidence 16.5/25 ROA 3.9% · ROE 8.9% · GNPA — 68% evidence 4.3/20 P/BV 9.58× · P/BV÷ROE 1.08 70% evidence 8.3/20 RS sector -6.9% · RS bench -7.8% · 1Y -1.9%4 of 12 weeks ahead 100% evidence
Exact sum: 17.5 + 16.5 + 4.3 + 8.3 = 46.6 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
14Jefferies Financial Group Inc.JEF 45.1/100Mixed-negative evidence80% evidence BREAKING OUT 21.6/35 Income 21.4% · PAT 39.5% 81% evidence 8.5/25 ROA 0.3% · ROE 2.4% · GNPA — 68% evidence 6.7/20 P/BV 1.01× · P/BV÷ROE 0.42 70% evidence 8.3/20 RS sector -8.5% · RS bench -9.5% · 1Y -4.7%9 of 12 weeks ahead 100% evidence
Exact sum: 21.6 + 8.5 + 6.7 + 8.3 = 45.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
15MarketAxess Holdings Inc.MKTX 45.0/100Mixed-negative evidence60% evidence TURNING 15.1/35 Income — · PAT — 26% evidence 14.8/25 ROA 3.1% · ROE 5.1% · GNPA — 68% evidence 6.0/20 P/BV 3.26× · P/BV÷ROE 0.64 70% evidence 9.1/20 RS sector -10.1% · RS bench -10.8% · 1Y -13.2%1 of 12 weeks ahead 100% evidence
Exact sum: 15.1 + 14.8 + 6 + 9.1 = 45 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
16TeraWulf Inc.WULF 44.8/100Thin evidence · provisional55% evidence FADING 19.3/35 Income 28% · PAT — 45% evidence 4.4/25 ROA -4.1% · ROE -897.3% · GNPA — 68% evidence 9.8/20 P/BV -77.86× · P/BV÷ROE — 10% evidence 11.3/20 RS sector 7.5% · RS bench 6% · 1Y 275.3%8 of 12 weeks ahead 100% evidence
Exact sum: 19.3 + 4.4 + 9.8 + 11.3 = 44.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
17BGC Group, Inc.BGC 43.9/100Mixed-negative evidence60% evidence BASING 16.8/35 Income — · PAT — 26% evidence 9.2/25 ROA 0.4% · ROE 5.8% · GNPA — 68% evidence 5.5/20 P/BV 4.63× · P/BV÷ROE 0.8 70% evidence 12.4/20 RS sector 1.1% · RS bench 0.1% · 1Y 9.2%5 of 12 weeks ahead 100% evidence
Exact sum: 16.8 + 9.2 + 5.5 + 12.4 = 43.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
18Tradeweb Markets Inc.TW 42.5/100Mixed-negative evidence60% evidence BASING 18.5/35 Income — · PAT — 26% evidence 13.8/25 ROA 2.3% · ROE 2.9% · GNPA — 68% evidence 4.8/20 P/BV 3.17× · P/BV÷ROE 1.09 70% evidence 5.4/20 RS sector -17.9% · RS bench -18.6% · 1Y -25.8%0 of 12 weeks ahead 100% evidence
Exact sum: 18.5 + 13.8 + 4.8 + 5.4 = 42.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
19Riot Platforms, Inc.RIOT 42.3/100Thin evidence · provisional55% evidence FADING 15.3/35 Income 42.3% · PAT — 45% evidence 4.5/25 ROA -14% · ROE -18.7% · GNPA — 68% evidence 9.8/20 P/BV 1.96× · P/BV÷ROE — 10% evidence 12.7/20 RS sector 9.9% · RS bench 8.3% · 1Y 94.6%10 of 12 weeks ahead 100% evidence
Exact sum: 15.3 + 4.5 + 9.8 + 12.7 = 42.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
20Galaxy Digital Inc.GLXY 39.7/100Thin evidence · provisional53% evidence ASLEEP 22.4/35 Income 25.5% · PAT — 45% evidence 5.5/25 ROA -2.8% · ROE -10.6% · GNPA — 68% evidence 10.0/20 P/BV — · P/BV÷ROE — 0% evidence 1.8/20 RS sector -24.8% · RS bench -25.9% · 1Y -20.3%7 of 12 weeks ahead 100% evidence
Exact sum: 22.4 + 5.5 + 10 + 1.8 = 39.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
21Robinhood Markets, Inc.HOOD 38.6/100Mixed-negative evidence60% evidence BREAKING OUT 17.1/35 Income — · PAT — 26% evidence 10.9/25 ROA 1% · ROE 6.5% · GNPA — 68% evidence 3.4/20 P/BV 9.51× · P/BV÷ROE 1.46 70% evidence 7.2/20 RS sector -17.2% · RS bench -18.1% · 1Y -18.4%10 of 12 weeks ahead 100% evidence
Exact sum: 17.1 + 10.9 + 3.4 + 7.2 = 38.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
22Houlihan Lokey, Inc.HLI 36.3/100Mixed-negative evidence60% evidence BASING 14.3/35 Income — · PAT — 26% evidence 13.8/25 ROA 2% · ROE 3.5% · GNPA — 68% evidence 4.4/20 P/BV 4.11× · P/BV÷ROE 1.17 70% evidence 3.8/20 RS sector -30.6% · RS bench -31.2% · 1Y -32.1%0 of 12 weeks ahead 100% evidence
Exact sum: 14.3 + 13.8 + 4.4 + 3.8 = 36.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
23IREN LimitedIREN 32.5/100Thin evidence · provisional55% evidence ASLEEP 16.3/35 Income 100% · PAT — 45% evidence 4.8/25 ROA -4.9% · ROE -12.1% · GNPA — 68% evidence 9.6/20 P/BV 4.39× · P/BV÷ROE — 10% evidence 1.8/20 RS sector -17.2% · RS bench -18.4% · 1Y 121.4%6 of 12 weeks ahead 100% evidence
Exact sum: 16.3 + 4.8 + 9.6 + 1.8 = 32.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
24Circle Internet Group, Inc.CRCL 25.7/100Adverse evidence70% evidence ASLEEP 12.5/35 Income 51.4% · PAT -146.2% 71% evidence 6.6/25 ROA 0.1% · ROE 2.1% · GNPA — 68% evidence 3.2/20 P/BV 6.89× · P/BV÷ROE 3.28 70% evidence 3.4/20 RS sector -40.6% · RS bench -41.2% · 1Y -60.2%2 of 12 weeks ahead 70% evidence
Exact sum: 12.5 + 6.6 + 3.2 + 3.4 = 25.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
25Figure Technology Solutions, Inc.FIGR 52.6/100Thin evidence · provisional47% evidence ASLEEP 23.8/35 Income 67.8% · PAT 100% 45% evidence 13.9/25 ROA 2.4% · ROE 5.4% · GNPA — 68% evidence 4.9/20 P/BV 5.76× · P/BV÷ROE 1.07 70% evidence 10.0/20 RS sector — · RS bench — · 1Y —2 of 12 weeks ahead 0% evidence
Exact sum: 23.8 + 13.9 + 4.9 + 10 = 52.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
26Hut 8 Corp.HUT 52.2/100Thin evidence · provisional41% evidence FADING 19.4/35 Income 100% · PAT — 29% evidence 8.7/25 ROA — · ROE -18.9% · GNPA — 34% evidence 9.8/20 P/BV 3.83× · P/BV÷ROE — 10% evidence 14.3/20 RS sector 47.6% · RS bench 45.2% · 1Y 420.1%11 of 12 weeks ahead 100% evidence
Exact sum: 19.4 + 8.7 + 9.8 + 14.3 = 52.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
27Bitmine Immersion Technologies, Inc.BMNR 35.2/100Thin evidence · provisional42% evidence BASING 16.2/35 Income — · PAT — 26% evidence 6.2/25 ROA 0.2% · ROE -1.4% · GNPA — 68% evidence 9.8/20 P/BV 0.96× · P/BV÷ROE — 10% evidence 3.0/20 RS sector -45.2% · RS bench -45.8% · 1Y -64.8%0 of 12 weeks ahead 70% evidence
Exact sum: 16.2 + 6.2 + 9.8 + 3 = 35.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. Financial companies use P/BV÷ROE and asset quality; PEG, industrial OPM and ROCE are excluded. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

16 · Frequently asked questions

Frequently asked questions

What is The Charles Schwab Corporation's stock price today?

The Charles Schwab Corporation trades at $106, +11.3% over the past year. The company is valued at $185 B. The stock sits at 100% of its 52-week range of $87–$106, +11.2% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 6 weeks in. — as of 5 August 2026.

What were The Charles Schwab Corporation's latest quarterly results?

The Charles Schwab Corporation reported total income of $7.1 B and net profit of $2.8 B for the Jun 26 quarter. Income rose 20.9% and profit rose 31.5% year on year. Earnings per share were $1.54. The net margin was 39.6%, 3.2 pp higher than a year earlier. — as of 5 August 2026.

What is The Charles Schwab Corporation's revenue?

The Charles Schwab Corporation reported revenue of $7.1 B in the Jun 26 quarter, +20.9% year on year. For the full FY25 fiscal year, revenue was $23.9 B (+22.0%). Over the last 4 years revenue compounded at 6.6% a year. — as of 5 August 2026.

What is The Charles Schwab Corporation's profit?

The Charles Schwab Corporation earned $2.8 B of net profit in the Jun 26 quarter, +31.5% year on year — the 9th straight quarter of growth. Full-year FY25 profit was $8.8 B. The net margin ran 39.6% in the latest quarter. — as of 5 August 2026.

What is The Charles Schwab Corporation's market cap?

The Charles Schwab Corporation's market capitalisation is $185 B at a stock price of $106. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.

What is The Charles Schwab Corporation's P/BV ratio?

The Charles Schwab Corporation trades at a P/BV of 3.7×, at the 90th percentile of its own 5-year range, against a long-run median of 3.0×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.

Does The Charles Schwab Corporation pay a dividend?

Yes — The Charles Schwab Corporation declared $0.32 per share for Mar 26, and $1.13 per share across the last four reported quarters. The latest quarter is up 18.5% on the same quarter a year earlier. — as of 5 August 2026.

What is The Charles Schwab Corporation's dividend per share?

The Charles Schwab Corporation's most recently declared dividend is $0.32 per share for Mar 26, giving $1.13 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 5 August 2026.

What is The Charles Schwab Corporation's dividend yield?

The Charles Schwab Corporation's trailing dividend yield is 1.06%: $1.13 declared per share across the last four reported quarters, against a share price of $106. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 5 August 2026.

Is The Charles Schwab Corporation overvalued?

On its own history, The Charles Schwab Corporation looks expensive against its own history: its P/BV of 3.7× sits at the 90th percentile of its 5-year range (long-run median 3.0×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: the net margin is the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 5 August 2026.

Is The Charles Schwab Corporation growing?

Yes — The Charles Schwab Corporation is growing: latest-quarter revenue +20.9% year on year, profit +31.5%, and the the net margin +3.2 pp at 39.6%. The 4-year compound rates are 6.6% (revenue) and 10.9% (profit). The earnings engine currently reads: improving — as of 5 August 2026.

How is The Charles Schwab Corporation performing?

The Charles Schwab Corporation is in a confirmed uptrend, 6 weeks in. Its latest quarter's income rose 20.9% and profit rose 31.5% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 4 weeks. This describes what the data did, not a rating. — as of 5 August 2026.

What stage is The Charles Schwab Corporation in?

Improving — EPS growth bottomed 8 quarters ago at −29.7% and has held its recovery at +47.8%, ROE lifting at 19.2%. The read comes from the last 12 quarters of growth (revenue growth +20.3% latest, profit growth +38.5% latest, eps growth +47.8% latest) plus the ROE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.

Is The Charles Schwab Corporation in an uptrend?

Yes — the price is in a confirmed uptrend (week 6 of stage 2), trading +11.2% versus its 200-day average and at 100% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.

Is The Charles Schwab Corporation beating the market?

On recent form, yes — The Charles Schwab Corporation has been ahead of the S&P 500 on a trailing-13-week view for 4 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +313% against the S&P 500's +263% — ahead of the index over the full window. — as of 5 August 2026.

Will The Charles Schwab Corporation's stock price go up?

This page publishes no price forecast for The Charles Schwab Corporation. What it measures instead: the stock price is $106, the price is in a confirmed uptrend 6 weeks in. Its P/BV of 3.7× sits at the 90th percentile of its own 5-year range. — as of 5 August 2026.

Is the market betting against The Charles Schwab Corporation?

No — short interest is 0.0% of The Charles Schwab Corporation's tradable float. That is a low reading: the crowd is not positioned against this stock. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.

Is The Charles Schwab Corporation's loan book healthy?

We do not hold quarterly loan-book quality numbers for The Charles Schwab Corporation, so this page says that plainly. The cleanest available reads are revenue growth (+22.0% in FY25) and the net margin on it (39.6%) — as of 5 August 2026.

Where is The Charles Schwab Corporation in its business cycle?

The Charles Schwab Corporation's FY25 net margin was 37.0%, against a 5-year band of 26.9%–37.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 39.6%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.

What could break the The Charles Schwab Corporation story?

The sharpest disagreement: annual EPS moved +55.5% against a +11.3% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.

Is The Charles Schwab Corporation a stock worth studying right now?

This is not investment advice. The machine read: The Charles Schwab Corporation's earnings have outrun its stock. EPS grew +55.5% in a year against a +11.3% price move. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI